Authors
Latest:
Breakthrough Study in Image-Guided Prostate Cancer TreatmentPublished OPTIMUM Trial results compares high-resolution micro-ultrasound with MRI when considering prostate biopsy.
Latest:
Follow-Up After Negative Bone/CT in Prostate Cancer With Molecular RecurrenceDr Raoul Concepcion leads a multidisciplinary expert panel in a discussion about the challenges of long-term follow-up of prostate cancer in patients with negative bone/CT but positive molecular indicators of recurrence.
Latest:
MRI-based screening emerging as viable alternative to PSA testing“MRI-based screening showed lower proportions of screening-positive cases, lower false positive rates, and higher PPVs [positive predictive values] than those of PSA-based screening,” noted Taek Min Kim, MD.
Latest:
Is greater patient control of their personal health records a plus for physicians?The Cures Act has teeth and consumers are becoming increasingly aware of their right to obtain their information.
Latest:
DFS end point not reached with adjuvant nivolumab for locally advanced high-risk RCCPatient subgroups that favored nivolumab vs placebo included patients with sarcomatoid features (HR, 0.42; 95% CI, 0.17-1.07), PD-L1 expression of 1% or greater (HR, 0.53; 95% CI, 0.22-1.29), and those with lower limit of normal hemoglobin at baseline (HR, 0.49; 95% CI, 0.25-1.49).
Latest:
Moffitt Study Suggests Improvements Needed for Patient-Reported Outcome Data in Genitourinary Cancer Clinical Studies“Our data showed a considerable gap in reporting patient-reported outcomes and in the quality of design and conduct of patient-reported outcomes-related trial endpoints," said Jad Chahoud, MD, MPH.
Latest:
Addressing Remaining Unmet Needs in mCRPCPanelists discuss how future trials in metastatic castration-resistant prostate cancer (mCRPC) should focus on developing reliable biomarker-driven treatment selection strategies to optimize sequencing decisions and identify which patients will benefit most from specific therapies or combinations, particularly as the treatment landscape becomes increasingly complex.
Latest:
Emulating target trials using observational evidence to inform clinical decision-making"The emulation framework lends the design and conduct of observational analyses some of the rigor required for the planning of a randomized trial. In doing so, it provides an innovative and principled approach to improve the evidence base on the comparative effectiveness of interventions," writes Boris Gershman, MD, and Aaron Fleishman, MPH.
Latest:
Ascension cyberattack’s impact felt in multiple statesSome Ascension hospitals continue to divert ambulances to other facilities for emergency treatment, but some of the system’s hospitals are accepting all patients.
Latest:
BLUES trial: Silicone stents may improve patient careThe study compared patient experiences with silicone vs polyurethane ureteral stents.
Latest:
Future Landscape of Prostate Cancer and Rectal SpacersThe expert panel concludes their discussion with a look toward the future of prostate cancer treatment and the evolving role of rectal spacers.
Latest:
Can remote patient monitoring help combat the staffing shortage?"As more patients become interested in remote patient monitoring and case studies continue to show improved patient outcomes, practices must seek ways to integrate these tools into their workflows," writes Lucienne Marie Ide, MD, PhD.
Latest:
Unmet Needs and Investigational Therapies in mCSPCDr Jason Hafron concludes his discussion of mCSPC by highlighting the need to work towards a cure for the disease, and two major clinical trials investigating triplet treatment regimens.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Chronic care management in the urologic oncology settingCCM programs can engage multiple providers to care for patients while reducing in-person visits.
Latest:
What you need to know about providing telehealth in 2023Jeremy D. Sherer, JD, explains everything physicians need to know about using telemedicine in their practice in 2023.
Latest:
Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2Enzalutamide plus talazoparib significantly extended overall survival vs enzalutamide alone in mCRPC.
Latest:
When it comes to urology teaching or learning opportunities, just say yes"Despite the uncertain times, I am grateful to be a student in the field of medicine, where compassion is one of the traits that defines its practitioners," says PA student Steffanie Robertus.
Latest:
John Taylor, III, MD, on novel options in NMIBCJohn A. Taylor, III, MD, MS, discussed the new wealth of options in non–muscle invasive bladder cancer, specifically highlighting detalimogene voraplasmid.
Latest:
Unmet Needs and Treatment Gaps in Prostate CancerThe panel concludes by addressing unmet needs in prostate cancer management, with a particular focus on improving risk stratification methods.
Latest:
Testicular Cancer Awareness Month: Advances and controversies in testicular cancer care"We’ve achieved a lot, but the focus now must shift from cure alone to comprehensive, patient-centered care," says Vladimir Hugec, MD.
Latest:
Comparing Leuprolide Formulations in Advanced Prostate CancerIn the third article of the series, Melanie McGilloway, NP-C, an advanced practice provider at Genesis Urology in San Diego, discusses the various formulations of leuprolide, a gonadotropin-releasing hormone (GnRH) agonist used for treating advanced prostate cancer.
Latest:
Study points to increased public interest in vaginal estrogen"What's important here is that there's an increased public interest in this vaginal estrogen therapy," says Elia Abou Chawareb, MD.
Latest:
Management of BCG-unresponsive NMIBC"An alternative off-label option for patients with BCG-unresponsive NMIBC is sequential intravesical gemcitabine and docetaxel (Gem/Doce)," write Rachel Passarelli, MD, and Vignesh T. Packiam, MD.
Latest:
Nadofaragene firadenovec maintains safety, efficacy in real-world population"The implication for real-world decision-making is that this drug appears to hold up to what was seen in the trial," says Mark D. Tyson II, MD, MPH.
Latest:
Ellen Cahill, MD, on chaperone use for genitourinary exams"I think it would be really nice if we did have standardized guidelines on who could serve as a chaperone," says Ellen Cahill, MD.
Latest:
Legislation improves accessibility to mental health programs for cliniciansCongress has taken actions aimed at protecting arrangements in which hospitals and other entities provide bona fide mental health improvement, behavioral health improvement, or maintenance programs to physicians and other clinicians.
Latest:
Radium-223 is associated with low rates of AEs, treatment discontinuation for bone metastatic CRPCOf note, 55% of patients received a full course (6 injections) of radium-223 injections, and 67% received 5 of the 6 injections.
